A retrospective study of real-world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia

BACKGROUND: Real-world evidence on factor Xa inhibitor (rivaroxaban) prescribing patterns, safety, and efficacy in patients with non-valvular atrial fibrillation (NVAF) and venous thromboembolism (VTE) is rare. Herein, we sought to examine the above outcomes in the largest academic center in the Kin...

Descripción completa

Detalles Bibliográficos
Autores principales: Alosaimi, Hind M., Alqahtani, Saeed, Balkhi, Bander, Alqahtani, Mishari, Alzamil, Faisal, Alhossan, Abdulaziz, Alqahtany, Fatmah S., Alharbi, Abdullah A., Alqahtani, Nawaf Abdullah, Albackr, Hanan, Elgohary, Ghada, Algahtani, Farjah H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2022
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9466595/
https://www.ncbi.nlm.nih.gov/pubmed/36105646
http://dx.doi.org/10.7717/peerj.13974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9466595/
https://www.ncbi.nlm.nih.gov/pubmed/36105646
http://dx.doi.org/10.7717/peerj.13974

Ejemplares similares